SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that the first patient has been dosed in RADIANT, a Phase 2 clinical trial comparing the safety and tolerability of the novel echinocandin, CD101, to standard-of-care fluconazole for the treatment of acute vulvovaginal candidiasis (VVC). RADIANT will evaluate two topical formulations of CD101, which is Cidara's lead antifungal drug candidate. "There have…

Results from Multiple Dose Phase 1 Trial of CD101 IV Supporting High-Exposure, Once-Weekly Dosing Will Be Presented For the First Time SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that data from preclinical and clinical studies evaluating its lead antifungal product candidate, CD101, will be presented at the American Society for Microbiology (ASM) Microbe 2016 meeting in Boston from June…

SAN DIEGO, June 02, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016. Jeff Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at 10:00 a.m. EDT (7:00 a.m. PDT). The conference is being held in New York City. A live audio webcast…

-CD101 Topical designated for treatment of VVC and for prevention of recurrent VVC- SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that the U.S. Food and Drug Administration (FDA) has designated the company's novel antifungal product candidate, CD101 topical, as a Qualified Infectious Disease Product (QIDP), with Fast Track status for its development program. The designation is for the development…

SAN DIEGO, May 12, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the three months ended March 31, 2016 and provided an update on its corporate activities and product pipeline. First Quarter 2016 and Subsequent Highlights Phase 2 Candidemia Clinical Trial On Track: Cidara conducted an End-of-Phase 1 meeting with the FDA and has begun clinical site initiation…

Presentations to Highlight Results from the Phase 1 Study of Novel Echinocandin CD101 IV Demonstrating Excellent Safety and Supporting Once-Weekly Dosing SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that data from preclinical and clinical studies of its novel echinocandin, CD101, will be presented at the 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam,…

SAN DIEGO, April 05, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Needham & Company 15th Annual Healthcare Conference on Tuesday, April 12, 2016. Jeff Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at 3:00 p.m. EDT (12:00 p.m. PDT). The conference is being held in New York City. A…

SAN DIEGO, March 18, 2016 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the three months and full year ended December 31, 2015 and provided an update on its corporate activities and product pipeline. Fourth Quarter 2015 and Subsequent Highlights Announced Positive Data from Single and Multiple Dose Phase 1 Clinical Trials of CD101 IV; on track to initiate…

Orphan designation follows QIDP and Fast Track status for CD101 IV SAN DIEGO - Headline of release should read: Cidara Receives Orphan Drug Designation for Novel Echinocandin, CD101 IV, in Candidemia and Invasive Candidiasis (instead of Cidara Receives Orphan Drug Designation for Novel Echinocandin, CU101 IV, in Candidemia and Invasive Candidiasis) The corrected release reads: CIDARA RECEIVES ORPHAN DRUG DESIGNATION FOR NOVEL ECHINOCANDIN, CD101 IV, IN CANDIDEMIA AND INVASIVE CANDIDIASIS Orphan designation follows QIDP and…

Orphan designation follows QIDP and Fast Track status for CD101 IV SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its antifungal drug candidate, CD101 IV, for the treatment of candidemia and invasive candidiasis. Orphan drug designation of CD101 provides Cidara eligibility for seven years of market…